Authors:
Yao, WQ
Wasserman, ZR
Chao, M
Reddy, G
Shi, E
Liu, RQ
Covington, MB
Arner, EC
Pratta, MA
Tortorella, M
Magolda, RL
Newton, R
Qian, MX
Ribadeneira, MD
Christ, D
Wexler, RR
Decicco, CP
Citation: Wq. Yao et al., Design and synthesis of a series of (2R)-N-4-hydroxy-2-(3-hydroxybenzyl)-N-1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors, J MED CHEM, 44(21), 2001, pp. 3347-3350
Authors:
Gilligan, PJ
Baldauf, C
Cocuzza, A
Chidester, D
Zaczek, R
Fitzgerald, LW
McElroy, J
Smith, MA
Shen, HSL
Saye, JA
Christ, D
Trainor, G
Robertson, DW
Hartig, P
Citation: Pj. Gilligan et al., The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-alpha]-pyrimidine: A corticotropin-releasing factor (hCRF(1)) antagonist, BIO MED CH, 8(1), 2000, pp. 181-189
Authors:
He, LQ
Gilligan, PJ
Zaczek, R
Fitzgerald, LW
McElroy, J
Shen, HSL
Saye, JA
Kalin, NH
Shelton, S
Christ, D
Trainor, G
Hartig, P
Citation: Lq. He et al., 4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine: A portent, orally bioavailable CRF1 receptor antagonist, J MED CHEM, 43(3), 2000, pp. 449-456